DOW JONES NEWSWIRES Map Pharmaceuticals Inc. (MAPP) reported positive study data related to its investigational drug Levadex, an inhaled treatment for migraines. Analysis showed that Levadex--the inhaled version of a drug used for decades in emergency rooms and doctors' offices through an intravenous line--was "effective" in treating a migraine attack with moderate or severe pain when given as soon as the initial migraine onset and as late as eight hours after the start of the migraine, MAP said. Another analysis also showed Levadex was "both effective and well-tolerated" in migraine patients with asthma. Earlier this year, Map said the U.S. Food and Drug Administration wouldn't require a second efficacy trial for Levadex, which last year met all four of its primary endpoints in the efficacy portion of its late-stage trial. In May, Map reported a wider first-quarter loss than a year earlier as it saw no collaboration revenue. The company's products are still in development. Shares closed at $12.71 on Tuesday and was inactive premarket. The stock has risen 15% in the past year. -By Nathan Becker, Dow Jones Newswires; 212-416-2855; nathan.becker@dowjones.com
